Novel Exenatide Analogs with Peptidic Albumin Binding Domains: Potent Anti-Diabetic Agents with Extended Duration of Action

Odile E. Levy, Carolyn M. Jodka, Shijun Steven Ren, Lala Mamedova, Abhinandini Sharma, Manoj Samant, Lawrence J. D’Souza, Christopher J. Soares, Diane R. Yuskin, Li Jenny Jin, David G. Parkes, Krystyna Tatarkiewicz, Soumitra S. Ghosh*

Amylin Pharmaceuticals LLC, San Diego, California, United States of America

Abstract

The design, synthesis and pharmacology of novel long-acting exenatide analogs for the treatment of metabolic diseases are described. These molecules display enhanced pharmacokinetic profile and potent glucoregulatory and weight lowering actions compared to native exenatide. [Leu^{14}]exenatide-ABD is an 88 residue peptide amide incorporating an Albumin Binding Domain (ABD) scaffold. [Leu^{14}]exenatide-ABP is a 53 residue peptide incorporating a short Albumin Binding Peptide (ABP). [Leu^{14}]exenatide-ABD and [Leu^{14}]exenatide-ABP exhibited nanomolar functional GLP-1 receptor potency and were metabolically stable in vitro in human plasma and in a pancreatic digestive enzyme mixture. Both molecules displayed picomolar and nanomolar binding association with albumin across multiple species and circulating half lives of 16 and 11 hours, respectively, post a single IV dose in rats. Unlike exenatide, both molecules elicited robust glucose lowering when injected 1 day prior to an oral glucose tolerance test, indicative of their extended duration of action. [Leu^{14}]exenatide-ABD was compared to exenatide in a Lepr^db/db mouse model of diabetes. Twice-weekly subcutaneously dosed [Leu^{14}]exenatide-ABD displayed superior glucose lowering and weight loss in diabetic mice when compared to continuously infused exenatide at the same total weekly dose. A single oral administration of each molecule via an enteric coated capsule to cynomolgus monkeys showed superior pharmacokinetics for [Leu^{14}]exenatide-ABD as compared to [Leu^{14}]exenatide-ABP with detectable exposure longer than 14 days. These studies support the potential use of these novel long acting exenatide analogs with different routes of administration for the treatment of type 2 diabetes.

Introduction

Peptide hormone-based therapeutics deliver significant therapeutic benefits while displaying exquisite receptor selectivity. While insulins have long been a treatment mainstay for diabetes, the development of peptide drugs from somatostatin [1], calcitonin [2,3], parathyroid hormone (PTH) [4], vasopressin [5], and glucagon like peptide-2 (GLP-2) [6] classes have become important treatment options for metabolic indications. With the recent introduction of Byetta™, Victoza™, Lyxumia® and Bydureon™, the GLP-1-based drug class has emerged as an important therapeutic regimen for treating patients with type 2 diabetes. These anti-diabetic agents illustrate product differentiation based on differences in efficacy, tolerability, frequency of administration and device presentation.

Long-acting injectable peptide drugs, given by injection, afford greater convenience and promote increased compliance due to less frequent administration. The design of such drugs needs to address proteolytic degradation and renal filtration which plays a significant role in their clearance from the bloodstream. Efforts to reduce renal clearance have focused on increasing molecular size beyond the 60 kDa renal threshold [7] through the covalent fusion of the bioactive molecule to molecular scaffolds such as polyethylene glycol (PEG) polymers [8,9,10,11], XTEN [12,13], polysaccharides, large natural proteins such as Fc [14,15,16] and albumin [17].

Alternate strategies involve modification of peptide and protein drugs to allow a reversible non-covalent association to serum albumin, resulting in half life extension commensurate with their albumin binding affinity [18,19,20,21]. These approaches take advantage of the high abundance of serum albumin in mammalian sera, its wide tissue distribution and extended half-life resulting from its large molecular size and neonatal Fc receptor (Fc-Rn) mediated cell recycling [22,23,24]. The half-life of serum albumin is directly proportional to size of species, as exemplified by half-lives in rabbits and humans of 4.6–6.2 and 19 days, respectively [25]. Thus, fatty acid acylation of peptides has emerged as a successful half-life extension approach via non-covalent association...
of the fatty acid alkyl moiety with albumin, and is exemplified by the once-daily anti-diabetic drugs Insulin detemir [26,27] and liraglutide [28,29]. Their protracted effect is attributed to drug self association that delays absorption, and their intermittent association with circulating albumin that also protects against enzymatic degradation.

Our half-life extension strategy focused on the fusion of bio-active peptides with small peptide motifs that display high affinity for albumins across species. Albumin Binding Peptides (ABP) and Albumin Binding Domains (ABD) have been reported in the literature. Dennis et al [19] have used phage display to identify a short albumin-binding peptide, that when recombiantly fused to an immunoglobulin fragment D3H44-Fab, improved its half life by 37 fold in rabbits and 26 fold in mice. In addition, an array of bacterial proteins showing high, and specific, affinity for various human plasma proteins have been identified and structural studies have elucidated homologous domains involved in the specific interaction with human albumin [30,31]. Lindhult, Johansson and Jonsson have reported on an ABD from the bacterial protein Streptococcal G (strain 148) that can be molecularly tuned to bind with nanomolar to femtomolar affinity to albumin [32,33,34]. The binding of ABD to albumin was shown not to interfere with albumin’s pH-dependent interaction with FcRn that is critical for its recycling mechanism [35].

In our studies, we utilized a previously reported ABP and an ABD licensed from Affibody AB (ABD035) as fusion partners for [Leu14]exenatide to generate potent, metabolically stable and long acting exenatide analogs with prolonged glucoregulatory action. The ABP and the ABD components are 1.4 and 5 kDa’s, respectively, and confer extended circulation half-lives to the conjugates through tight, reversible binding to plasma albumin. Our fusion strategy is amenable to chemical or recombinant manufacturing processes, and results in significantly smaller conjugates compared to those with molecular scaffolds such as Fc, XTEN and PEG. They display comparable half-life extension with preservation of biological potency, afford the ability to screen the molecules in animal models from different species and offer flexibility to deliver the fusion molecules by alternate routes of administration.

As a proof of concept study, an oral formulation of [Leu14]exenatide (also described as AC3174 in prior reports [36]), is an exenatide analog with leucine substituted for methionine at position 14 to prevent oxidation, and is very similar in its biological activity when compared to exenatide. The design strategy for our peptides was the C-terminal extension of [Leu14]exenatide with either the 46 amino acid sequence of ABD035 or the 11 amino acid sequence of ABP (Table 1) via a tripeptide linker. Both exenatide and [Leu14]exenatide are interchangeably referred to as parent peptides in this manuscript.

[Leu14]exenatide-ABD was assembled on Fmoc-Pro-Novasyn TGT resin (EMD Chemicals, Gibbstown, NJ) using standard solid phase peptide synthesis protocols on a Prelude automated peptide synthesizer (Protein Technology Inc, Tucson, AZ, 0.2 mmole scale). Fmoc amino acid residues were activated using 4.0 eq of 0.5 M O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate, 8.0 eq of 1 M disopropylethylamine in dimethylformamide (DMF) and double coupled for 1 hour. Fmoc group was removed by treatment with 20% (v/v) piperidine in DMF. Cleavage and deprotection was performed by treatment of the resin with reagent B (93% trifluoroacetic acid (TFA), 3% phenol, 3% water and 1% triisopropylsilane) for 3 hours. The cleaved peptide was precipitated using t-butyl methyl ether, pelleted by centrifugation and lyophilized. The pellet was re-dissolved in 10% acetonitrile/water (10–15 min), filtered and purified via reverse phase HPLC using C5 column and an acetonitrile/water gradient containing 0.1% TFA. The compound was re-purified via reverse phase HPLC C18 column using a shallower gradient. The purified compound was analyzed by ESI-MS (empirical weight 9462.86; mass found 9461.39). The pure peptide obtained as a TFA salt was used for all biological evaluations.

Similarly, [Leu14]exenatide-AB was assembled on Fmoc-Trp(Boc)-Novasyn TGT resin using standard solid-phase peptide synthesis protocols on a Prelude TMS peptide synthesizer on a 0.2 mmole scale. After cleavage of the peptide from the resin, the

Exenatide Analogs with Long Duration of Action

Materials and Methods

Ethics Statement

All studies were approved by the Institutional Animal Care and Use Committee at Amylin Pharmaceuticals, LLC, and at Xenometics LLC, in accordance with the Animal Welfare Act, AAALAC, and PHS regulations and/or guidelines.

Reagents

Liraglutide (Victozza® pen) was obtained from Cedar Pharmacy (Henderson, NV, www.cedarpharmacy.com) and dissolved in normal saline for use in mouse studies, or in assay buffer for the GLP-1 receptor functional assay. Synthetic human GLP-1 (7–36) and exenatide were purchased from Bachem (Torrance, CA, USA).

Animals

All animals were acclimated to the testing facility for at least 1 week prior to dosing. Rodent studies were conducted at Amylin Pharmaceuticals (San Diego, CA, USA) using male 14–20 week old Hsd:NIHS mice (n = 9–16 per group, body weight 31.1 ± 0.2 g) (Harlan, Indianapolis, IN, USA), male 6–week old B6.V-Lep+/J (ob/ob) mice (n = 10 per group, body weight 43.9 ± 0.3 g) (Jackson Laboratories Bar Harbor, ME), or male 13–14 week old Sprague Dawley (Hsd) rats (n = 4 per group, body weight 361.9 ± 2.6 g) (Harlan, Indianapolis, IN). Rodents were housed 1–3 per cage at 21–24°C with a 12 h light/dark cycle with ad libitum access to food and water with the exception of tests where fasting (no more than 16 h) was required. Non-human primate studies were outsourced to Xenometrics (Stübwell, KS, USA). Adult, male non-synomyosus monkeys (Macaca fascicularis) were obtained from SNBL USA or Covance (6.63 ± 0.50 years of age; 6.0–11.1 kg; n = 3 per group), and were singly housed in stainless steel cages with slatted flooring, in a conventional facility room with other Cynomolgus monkeys. Animal rooms were environmentally controlled (temperature, humidity and lighting) with continuous access to drinking quality water and a set amount of certified monkey biscuits. Enrichment was provided per SOP, 3–4 days per week and included stimulation of all the senses on a rotating basis. Welfare-related assessments were made on a daily basis by animal care and use technicians and an on-site veterinarian is notified of any health, welfare or behavioral issues. No intervention was necessary for the study. All housing, feeding and environmental enrichment procedures were conducted in compliance with the Animal Welfare Act, AAALAC, and PHS regulations and/or guidelines and Xenometrics SOP’s.

Peptide Synthesis

[Leu14]exenatide (also described as AC3174 in prior reports [36]), is an exenatide analog with leucine substituted for methionine at position 14 to prevent oxidation, and is very similar in its biological activity when compared to exenatide. The design strategy for our peptides was the C-terminal extension of [Leu14]exenatide with either the 46 amino acid sequence of ABD035 or the 11 amino acid sequence of ABP (Table 1) via a tripeptide linker. Both exenatide and [Leu14]exenatide are interchangeably referred to as parent peptides in this manuscript.

[Leu14]exenatide-ABD was assembled on Fmoc-Pro-Novasyn TGT resin (EMD Chemicals, Gibbstown, NJ) using standard solid phase peptide synthesis protocols on a Prelude automated peptide synthesizer (Protein Technology Inc, Tucson, AZ, 0.2 mmole scale). Fmoc amino acid residues were activated using 4.0 eq of 0.5 M O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate, 8.0 eq of 1 M disopropylethylamine in dimethylformamide (DMF) and double coupled for 1 hour. Fmoc group was removed by treatment with 20% (v/v) piperidine in DMF. Cleavage and deprotection was performed by treatment of the resin with reagent B (93% trifluoroacetic acid (TFA), 3% phenol, 3% water and 1% triisopropylsilane) for 3 hours. The cleaved peptide was precipitated using t-butyl methyl ether, pelleted by centrifugation and lyophilized. The pellet was re-dissolved in 10% acetonitrile/water (10–15 min), filtered and purified via reverse phase HPLC using C5 column and an acetonitrile/water gradient containing 0.1% TFA. The compound was re-purified via reverse phase HPLC C18 column using a shallower gradient. The purified compound was analyzed by ESI-MS (empirical weight 9462.86; mass found 9461.39). The pure peptide obtained as a TFA salt was used for all biological evaluations.

Similarly, [Leu14]exenatide-AB was assembled on Fmoc-Trp(Boc)-Novasyn TGT resin using standard solid-phase peptide synthesis protocols on a Prelude TMS peptide synthesizer on a 0.2 mmole scale. After cleavage of the peptide from the resin, the
lyophilized material was re-dissolved in 20% acetic acid (7–10 mg/ml) and oxidized with an iodine solution (0.125 M in acetic acid) for 10–15 minutes, filtered and purified via reverse-phase HPLC using C5 column and an acetonitrile/water gradient containing 0.1% TFA. The purified product was analyzed by ESI-MS and re-purified via reverse phase HPLC C18 column using a shallower gradient. Final peptide was analyzed by ESI-MS (empirical weight 5682.4; mass found 5681.76). The pure peptides shallower gradient. Final peptide was analyzed by ESI-MS and re-purified via reverse phase HPLC C18 column using a shallower gradient. Final peptide was analyzed by ESI-MS (empirical weight 5682.4; mass found 5681.76). The pure peptides.

Table 1. Names and Sequences of Compounds.

| Compound       | Sequence                                      |
|----------------|-----------------------------------------------|
| GLP-1 (7–36)   | HAEGTFTSDLVYYLEGQAAKEFIAWLVKGR-NH₂           |
| Exenatide      | HEGEGTFTSDLVYYYLEGQAAKEFIAWLVKGR-NH₂         |
| [Leu₁⁴]exenatide | HEGEGTFTSDLQKLEEEAVRLFIEWLKNGGPSSGAPPPS-NH₂  |
| [Leu₁⁴]exenatide-ABP | HEGEGTFTSDLQKLEEEAVRLFIEWLKNGGPSSGAPPPS-GGDD-lg-cyclo[CLPRWGC]LW-OH |
| [Leu₁⁴]exenatide-ABD | HEGEGTFTSDLQKLEEEAVRLFIEWLKNGGPSSGAPPPS-GGDD-lg-cyclo[CLPRWGC]LW-OH |
| Liraglutide    | HAEGTFTSDLVYYLEGQAA[N-epsilon(gamma-Glu(N-alpha-hexadecanoyl))-Lys]EFIAWLVKGRG-OH |
| ABD035         | LAEAKVLANRELKYGVSDFYKRLINKAKTVEGVEALKLHILAAP-OH |

Stability in Human Plasma

Standard solutions of the peptides (200 μM in PBS) were prepared and diluted in human plasma (1 ml; Bioreclamation, Long Island, NY) to a final concentration of 50 μM at 37°C. At 0, 1, 2, 3, 4, and 5 h, aliquots of 20 μl were removed, quenched with 5% phosphoric acid (100 μl) and the samples were analyzed as triplicates by using analytical HPLC coupled with a mass detector. [Leu₁⁴]exenatide and GLP-1 were used as positive and negative controls. The final results were normalized to the positive control and expressed as percent peptide remaining.

Stability in Pancreatic Digestive Enzyme Mix

Stability of peptides was also assessed in a mixture of amylase, lipase and protease (pancreatin, Cat.# P7545-25 g. Sigma-Aldrich, St. Louis, MO), which are digestive enzymes produced by pancreatic exocrine cells. Peptides (30 mM) in 50 mM phosphate buffer (pH 6.8) and citrate buffers (pH 4 & pH 5) were incubated for 2 hours in pancreatic mixture at 37°C (20:1 ratio of peptide to pancreatic mixture) (n = 3). The enzymatic reaction was stopped with the addition of 0.2 N HCl (final concentration of peptide 10 mM) at each time point. Samples taken at 0, 10, 20, 30, 60, and 120 min were analyzed for peptide stability by reverse-phase HPLC.

Intravenous (IV) Pharmacokinetics in Rats and Non-Human Primates

In all studies, blood samples were collected into tubes containing EDTA and were kept at approximately 5°C until and during centrifugation. Plasma, collected from the centrifuged blood samples, was stored at −70°C until analyzed for peptide concentration. Male drug-naïve Sprague Dawley rats received 2 nmol/kg of exenatide or [Leu₁⁴]exenatide-ABD or [Leu₁⁴]exenatide-ABP in phosphate buffer (PBS) as a bolus into the tail vein.

Monkeys were fasted overnight prior to dosing, and through approximately 2 hours post-dose, and received [Leu₁⁴]exenatide-ABD, 2.4 nmol/kg in pH 4 acetate buffer or [Leu₁⁴]exenatide-ABP, 2.4 nmol/kg in pH 7.4 phosphate buffer administered through an indwelling catheter in the cephalic vein. The test articles were supplied in ready to use IV solutions. All animals were dosed in the morning (09:09–09:33) and blood samples collected while in a restraint chair. The animals were housed in their standard cages between sample collections. Blood samples were collected from the cephalic or saphenous veins pre-dose and at various time points up to 14 days post-dose. The study consisted of 4 experimental groups containing 3 male nonhuman primates each dosed in a parallel design. The animals were selected based on their availability with no randomization being performed. The animals used came from the Xenometrics non-naïve colony. No
animals were sacrificed in the course of this study and all animals were returned to the non–naïve stock colony following completion of the study.

Oral Glucose Tolerance Test (OGTT) in Mice

All peptides were injected IP at t = −5 min into 4-hour fasted Hsd:NHS female mice. Glucose gavage (1.5 g/kg) was given at t = 0. Blood samples were taken from the tail at t = 30 min. In addition, peptides were administered 1 day prior to the glucose challenge to evaluate their duration of action in an OGTT.

Sub-chronic Dosing in Diabetic Lep^ob/ob Mice

Mice were singly housed and randomized into three treatment groups based on glycated hemoglobin A1c (HbA1c) prior to the 4-week study. [Leu^{14}]exenatide-ABD at 100 nmol/kg/dose in PBS was administered IP twice a week (BIW). To match the [Leu^{14}]exenatide-ABD total weekly dose, exenatide was administered at 30 nmol/kg/d in 30 mM Na-acetate buffer (pH 4.5) via continuous SC infusion using osmotic mini-pumps (ALZET® model 2002, Durect Corp., Cupertino, CA). To assure the same animal handling across all groups, [Leu^{14}]exenatide-ABD-treated mice received mini-pumps with infusion vehicle, the exenatide-treated group was injected BIW with PBS, and vehicle control mice were dosed BIW with PBS and implanted with mini-pumps delivering infusion vehicle. After 2 weeks, all mice were re-implanted with new mini-pumps with the same treatment administered for the next 2 week. HbA1c and body weight were assessed periodically. Following the study, all mice were sacrificed at 30 nmol/kg/d in 30 mM Na-acetate buffer (pH 4.5) via continuous SC infusion using osmotic mini-pumps (ALZET® model 2002, Durect Corp., Cupertino, CA). To assure the same animal handling across all groups, [Leu^{14}]exenatide-ABD-treated mice received mini-pumps with infusion vehicle, the exenatide-treated group was injected BIW with PBS, and vehicle control mice were dosed BIW with PBS and implanted with mini-pumps delivering infusion vehicle. After 2 weeks, all mice were re-implanted with new mini-pumps with the same treatment administered for the next 2 week. HbA1c and body weight were assessed periodically. Following the study, all mice were sacrificed with an overdose of isoflurane.

Formation of Enteric Coated Capsule for Oral Delivery in Non-Human Primates

Sodium chenodeoxycholate in water (0.12 M) was sealed in a glass container and heated. After dissolution was complete, propyl gallate (0.12 M) and sucrose (0.06 M) were added. The solution was allowed to cool to room temperature and pH was adjusted to 7.4 using 1 N NaOH solution. Test peptide and water were added to obtain a final concentration of the test peptide (0.02 mM). The solution was lyophilized and the dry powder was filled into gelatin capsule (size 3, Torpac, Fairfield, NJ). The filled capsules were subsequently enteric coated with a suspension consisting of isopropyl alcohol, acetone and water according to guidelines provided by the capsule manufacturer.

Pharmacokinetic Studies in Non-Human Primates

Cynomolgus monkeys were dosed PO with either [Leu^{14}]exenatide-ABP or [Leu^{14}]exenatide-ABD with a single enteric coated capsule (equivalent to 41 nmol/kg exenatide), followed by up to a 3 ml flush of water to ensure delivery completion. Blood samples were collected from the cephalic or saphenous veins predose and at 0.25, 0.5, 1, 2, 3, 4, 8, 24 and 48 h post-dose and on days 5, 7, 10, 12, and 14. A half banana was given following the 2 h PK sample collection, ½ daily ration was given ~4 h post-dose and the remaining daily rations were fed ~6 h post-dose. Absolute bioavailability was calculated by dividing the dose-adjusted AUC of the PO PK curve by the AUC of the IV PK curve.

Biochemical Analysis

Plasma glucose was measured using a OneTouch® Ultra glucose meter (LifeScan, Inc., Johnson & Johnson Co, Milpitas, CA). Whole blood HbA1c was measured using the Olympus AU680 clinical analyzer (Olympus America, Irving, TX). Plasma concentrations of peptides were measured using a validated two-site “sandwich” ELISA as described previously [37] using two monoclonal antibodies that target the N- and C-terminal regions of exenatide. The linear range of the standard curve was 40–5,120 pg/ml, with the lower limit of quantitation at 60 pg/ml and the upper limit of quantitation at 5,000 pg/ml.

Statistical Analyses

Results are presented as means ± SEM, graphed and analyzed using GraphPad Prism 5®. The potency of peptides in the in vitro functional assay and in an OGTT was determined by the analysis of concentration-response curves using non-linear regression analysis. Statistical differences (p<0.05) between groups in the sub-chronic Lep^ob/ob mouse study were identified with one-way ANOVA followed by post-hoc Tukey’s test. Albumin binding data shown in Table 2 are presented as mean ± SD.

Results

Albumin Binding Affinity

Binding constants (overall affinity K_D (pM), association rate constant k_a (M⁻¹ s⁻¹) (k_in) and dissociation rate constant k_d (s⁻¹) (k_off)) determined for [Leu^{14}]exenatide-ABP and [Leu^{14}]exenatide-ABD to albumin from different species are presented in Table 2. The result show that both peptides associate with serum albumins of all species with high affinity. In general, the affinity of the ABD fused exenatide molecule to albumins was several orders of magnitude higher than its ABP fused exenatide counterpart. With respect to human albumin an association rate constant k_a of 1.51±0.03×10⁶ M⁻¹ s⁻¹ and a dissociation rate constant k_d of 7.47±0.06×10⁻⁶ s⁻¹ (based on a 3 h measurement), resulted in an overall affinity K_D of 4.94±0.09 pM for [Leu^{14}]exenatide-
ABD. This value corresponds closely to that of the unconjugated ABD035 \(K_D = 16.1 \pm 0.4 \text{ pM}\).

**In Vitro Activity and Stability of Peptides**

Results from in vitro studies are summarized in Table 3. \[\text{Leu}^{14}\]exenatide-ABP and \[\text{Leu}^{14}\]exenatide-ABD were functionally active, with an EC\(_{50}\) of 0.066 nM and 0.63 nM, respectively in a GLP-1 receptor functional assay that contained 0.1% BSA in the assay medium (Figure 1). \[\text{Leu}^{14}\]exenatide-ABD receptor functional activity was not affected by the presence of higher concentrations of serum albumin of different species (EC\(_{50}\)’s obtained in the presence of 1% serum albumin: bovine 0.23 nM, human 0.21 nM, rat 0.24 nM). The 100-fold reduction of potency in the receptor functional assay for \[\text{Leu}^{14}\]exenatide-ABD when compared to \[\text{Leu}^{14}\]exenatide (0.006 nM) is possibly due to steric hindrance caused by the ABD fused to the C-terminus of the peptide. Similar to the parent peptides, \[\text{Leu}^{14}\]exenatide-ABD was stable in human plasma over 5 hours. However some degradation of \[\text{Leu}^{14}\]exenatide-ABP was noted. Significant degradation of all peptides occurred at pH 6.8 when exposed to a mixture of pancreatic enzymes. The stability in the pancreatin mix improved with the decrease of pH and degradation was negligible in the most acidic milieu (pH 4.0) for all peptides.

**Intravenous (IV) Pharmacokinetics in Rats and Non-Human Primates**

The pharmacokinetic (PK) profiles of the compounds intravenously dosed in rats were markedly extended versus the PK profile of exenatide. In rats, the half-life of the un-conjugated exenatide was 30 minutes, whereas the absolute calculated half-lives for \[\text{Leu}^{14}\]exenatide-ABP and \[\text{Leu}^{14}\]exenatide-ABD were 11 and 16 hours, respectively (Figure 2A). Furthermore, a single IV injection of \[\text{Leu}^{14}\]exenatide-ABP or \[\text{Leu}^{14}\]exenatide-ABD in monkeys showed detectable exposure up to two days and greater than 14 days, respectively (Figure 2B).

**OGTT in Mice**

When dosed 5 min prior to an oral glucose challenge at 25 nmol/kg, \[\text{Leu}^{14}\]exenatide-ABP and \[\text{Leu}^{14}\]exenatide-ABD blunted the rise in plasma glucose relative to vehicle-treated mice with efficacy comparable to exenatide or \[\text{Leu}^{14}\]exenatide (Table 3). However, when dosed 24 h prior to an oral glucose challenge at 25 nmol/kg, only \[\text{Leu}^{14}\]exenatide-ABP and \[\text{Leu}^{14}\]exenatide-ABD blunted the plasma glucose excursion relative to vehicle, indicative of their long duration of action. Liraglutide at the same dose had a similar glucose lowering effect. Exenatide was ineffective in this assay even at much higher doses (250 nmol/kg).

**Sub-chronic Dosing in Diabetic Lep\(^{ob/ob}\) Mice**

\(\text{Lep}^{ob/ob}\) mice were diabetic and obese prior to treatment, with a mean HbA1c value of 6.90 ± 0.11% and a mean BW of 45.7 ± 0.6 g. HbA1c values in control vehicle-treated mice increased from baseline by 1.59 ± 0.33% at the end of the 4 week study. Twice-weekly SC injections of \[\text{Leu}^{14}\]exenatide-ABD for 4 week resulted in a significant vehicle-corrected reduction in HbA1c (\(-1.78 \pm 0.16\%\)) vs. continuous infusion of exenatide at a similar total weekly dose of 210 nmol/kg/week (\(-0.55 \pm 0.27\%\)) or vehicle \((p<0.05)\) (Figure 3A). \[\text{Leu}^{14}\]exenatide-ABD decreased body weight gain by approximately 10%, comparable to the changes observed with exenatide infusion (Figure 3B). This reduction in weight gain was driven by comparable decreases in food intake (Fig. 3C) with \[\text{Leu}^{14}\]exenatide-ABD and exenatide.

### Table 3. In Vitro Activity, Metabolic Stability, and Plasma Glucose in OGTT.

| Compound            | GLP-1 Receptor Functional Assay  | OGTT DOA | OGTT | Glucose (mg/dl) |
|---------------------|----------------------------------|----------|------|----------------|
| GLP-1 (7–36)        |                                  |          |      |                |
| Exenatide           | 0.010                            | not active |      |                |
| \[\text{Leu}^{14}\]exenatide-ABP | 0.006                            | not active |      |                |
| \[\text{Leu}^{14}\]exenatide-ABD | 0.006                            | not active |      |                |
| \[\text{Leu}^{14}\]exenatide-ABD | 0.63                             | not active |      |                |
| Liraglutide         | 0.35                             | not active |      |                |
| AB0205              | 10.2                             | not active |      |                |

Stability results (expressed as a percentage of peptide remaining versus stable control peptide: \pm\ SEM). Replicates within each assay \(n=3\), except for exenatide and Liraglutide (\(n=2\)).
treatments, and in line with the reported anorexigenic action of exenatide [38].

Pharmacokinetic Studies in Non-Human Primates

A single enteric coated capsule was given orally to each cynomolgus monkey. While absolute calculated bioavailability for both [Leu14]exenatide-ABP and [Leu14]exenatide-ABD was <1%, detectable plasma exposure of [Leu14]exenatide-ABP was <50 pM at all time points, whereas exposure of [Leu14]exenatide-ABD was >50 pM for 7 days and detectable for 14 days (Figure 4). This confirmed the extended circulation time of the ABD molecule, consistent with its association with monkey albumin (half life of 11–13 days), and the potential for oral uptake of this molecule when suitably formulated.

No adverse events were reported in the above animal studies.

Discussion

The current study describes characterization of two novel long-acting exenatide analogs that were designed to have extended plasma circulation by virtue of their tight association with serum albumin, while retaining the key pharmacological actions of their parent hormone. [Leu14]exenatide-ABP is a fusion molecule that has [Leu14]exenatide conjugated to an albumin binding peptide via a Gly-Gly-Gly linker. [Leu14]exenatide-ABD is comprised of [Leu14]exenatide and an albumin binding domain from bacterial Streptococcus protein G that are linked via a Gly-Gly-Ser sequence.

Both molecules displayed extremely high affinity for serum albumin from various species. [Leu14]exenatide-ABD was found to bind to albumin with greater avidity than [Leu14]exenatide-ABP, and is comparable to un-conjugated ABD035 in its affinity. [Leu14]exenatide-ABD displayed a descending order of affinity for albumins from human, rat, monkey, dog and mouse, with a 50 fold difference in affinity for human (5 pM) and mouse (253 pM) albumins. Based on its picomolar affinities for albumins from various species and the presence of high concentration of serum albumin in blood, it is expected that [Leu14]exenatide-ABD will exist essentially in the bound state in vivo. Despite its tight binding to albumin, [Leu14]exenatide-ABD retained potent GLP-1 receptor functional activity in the presence of high concentrations of serum albumin (1%) of different species. This is surprising in part because liraglutide, a GLP-1 analog with much weaker albumin binding properties [29,39], has been reported to display significant activity only when dissociated from albumin [40]. We speculate that the ABD moiety in [Leu14]exenatide-ABD also functions as a spacer to minimize undesirable steric interactions between exenatide and the bound albumin, thereby permitting the exenatide component to interact with the GLP-1 receptor. The calculated half-lives of [Leu14]exenatide-ABD and [Leu14]exenatide-ABP in rats was determined to be 16 hours and 11 hours.
respectively, while the half lives of the non-conjugated exenatide molecules were less than 30 minutes. The terminal half-lives of liraglutide ranging from 4–8 hrs has been reported in mice, rats, rabbits and monkeys (see European Medicines Agency Assessment Report for Victoza; Doc. Ref: EMEA/379172/2009) and is approximately 4 hrs in rats [41]. This is in contrast to the above-mentioned half-lives for [Leu14]exenatide-ABP and [Leu14]exenatide-ABD, which are in line with the stronger affinity of the peptides for albumin.

We then evaluated the pharmacokinetic profile of the engineered peptides in higher mammal species. Intravenous dosing of [Leu14]exenatide-ABP and [Leu 14]exenatide-ABD in monkeys produced exposure of 2 days and greater than 14 days, respectively. In other studies, [Leu14]exenatide-ABD exposure after a single intravenous dose persisted up to four days in dogs (data not shown). The turnover of albumin in the cynomolgus monkey is about 11–13 days, and about 19 days in humans. Thus, allometric scaling combined with the observed strong affinity of [Leu14]exenatide-ABD for human albumin suggest that a duration of exposure of at least 14 days could be expected in human subjects. The shorter duration of exposure of [Leu14]exenatide-ABP in monkeys, coupled with its susceptibility to degradation in human plasma, led us to focus on [Leu14]exenatide-ABD for additional investigation in diabetic mice.

[Leu14]exenatide-ABP and [Leu14]exenatide-ABD were both full GLP-1 receptor agonists, albeit with somewhat reduced potency compared to native exenatide. A 100 fold loss of \textit{in vitro} functional activity of [Leu14]exenatide-ABD compared to exenatide may be attributed to steric hindrance associated with the larger peptide chain. This finding is consistent with the reduced receptor potencies reported for liraglutide (replicated in our studies, Table 3) and albugon that are GLP-1 analogs derivatized with a fatty acid functionality or conjugated to human serum albumin, respectively. Despite the loss in \textit{in vitro} potency,
Exenatide Analogs with Long Duration of Action

[Leu\textsuperscript{14}]exenatide-ABD and [Leu\textsuperscript{14}]exenatide-ABP retain the required exenatide-like activity to provide comparable glucoregulatory effects with longer duration of action in rodent models. It is known that while both native GLP-1 and exenatide show equivalent binding potency at the GLP-1 receptor [22,43], exenatide exhibits significantly greater effects for glucose lowering than GLP-1 as a consequence of its greater metabolic stability [44]. This analogy can be extended to explain our findings with native exenatide and exenatide-ABD, where a lower in vivo potency of exenatide-ABD is more than compensated by its superior pharmacokinetic properties to afford comparable pharmacodynamic effects.

The extended duration of glucoregulatory benefits with these exenatide analogs was demonstrated in studies in normal and diabetic rodents. In an acute OGTT, [Leu\textsuperscript{14}]exenatide-ABP, [Leu\textsuperscript{14}]exenatide-ABD and the parent exenatide molecule significantly lower plasma glucose when administered just prior to the oral glucose challenge, with ED\textsubscript{50} values of 3, 8 and 0.9 nmol/kg for [Leu\textsuperscript{14}]exenatide-ABD, [Leu\textsuperscript{14}]exenatide-ABP and [Leu\textsuperscript{14}]exenatide, respectively. However, only [Leu\textsuperscript{14}]exenatide-ABD and [Leu\textsuperscript{14}]exenatide-ABP elicited significant reduction in plasma glucose when administered 24 h prior to the glucose challenge.

In additional studies with [Leu\textsuperscript{14}]exenatide-ABD, robust HbA\textsubscript{1c} lowering was observed in diabetic Leph\textsubscript{dpb} mice, which received twice-weekly injections of [Leu\textsuperscript{14}]exenatide-ABD for 4 weeks. These effects were significantly greater than those obtained with continuous infusion of exenatide at a total weekly dose of [Leu\textsuperscript{14}]exenatide-ABD. The reduction of body weight gain seen with [Leu\textsuperscript{14}]exenatide-ABD was comparable to that observed for continuous infusion of native exenatide.

Attempts for oral delivery of peptides has been limited to a few therapeutic molecules such as somatostatin [45], salmon calcitonin [46], insulin [47] and Sandimmune™, an approved immunosuppressant drug. The harsh acidic environment in the stomach and enzymatic hydrolysis in the gut conspire in the rapid degradation and loss of peptides. In addition, large molecular size and physiochemical properties adversely affect uptake, resulting in very low bioavailability. Despite these limitations, we carried out proof of concept pharmacokinetic study for oral delivery in non-human primates.

In the study, cynomolgus monkeys were dosed orally with a single enteric coated capsule containing [Leu\textsuperscript{14}]exenatide-ABP or [Leu\textsuperscript{14}]exenatide-ABD. Once the capsule transited the stomach, it was designed to dissolve at the neutral pH in the intestine to release its contents to facilitate the peptide’s permeation across the mucosal barrier and intestinal cell wall barrier. Surprisingly, relatively rapid uptake of [Leu\textsuperscript{14}]exenatide-ABD in plasma was observed, and after about two hours, levels expected to be therapeutic based on exenatide exposure observed in the clinic (>30 pM) were achieved and were sustained over 7 days. It remains to be seen whether the flat pharmacokinetic profile and a relatively low C\textsubscript{max} noted in our study will enhance patient tolerability in future studies. The absolute oral bioavailability of [Leu\textsuperscript{14}]exenatide-ABD calculated in monkeys was <1%. Despite this relatively poor bioavailability, therapeutic concentrations of [Leu\textsuperscript{14}]exenatide-ABD were attained in plasma, and its extended plasma residence support the potential for weekly oral dosing.

In summary, we have shown that fusion of an exenatide analog to albumin binding motifs of various origin provide novel long acting analogs [Leu\textsuperscript{14}]exenatide-ABP and [Leu\textsuperscript{14}]exenatide-ABD that display potent glycemic control and significantly prolonged duration of action compared to their parent hormone. These molecules bind albumin with high affinity while in circulation, leading to their extended duration of action. The analogs are significantly smaller in molecular size compared to long-acting GLP-1 clinical candidates that rely on Fc, albumin or XTEN conjugation for half life extension, are amenable to production by cost-effective recombinant processes, and hence offer the promise of superior manufacturing cost of peptide per therapeutic dose. In addition, their albumin binding affinities can be tuned for daily or even weekly delivery via different administration routes. Long exposure of [Leu\textsuperscript{14}]exenatide-ABD obtained in non-human primates after oral delivery warrant further studies for optimization of the oral delivery formulations.

Acknowledgments

The authors are thankful to Tim Torchia for his intellectual contributions and discussions. We appreciate the discussions on the ABD platform with Affibody AB and the excellent technical assistance of Emmanuel Sablan, Clara Poluzzi, Christiane Villegas, Pamela Smith, Julie Hoyt, Jon Athanacico, Carrie Dolman, Yan Wang, Natasha Moshirian, Amy Diliberto and John Herich in conducting the study.

Author Contributions

Conceived and designed the experiments: OEL CMJ DGP SSG CJSt. Performed the experiments: KT SSR LJF LJDS MS LM DRY. Analyzed the data: CMJ OEL KT LJDS. Contributed reagents/materials/analysis tools: LJF MS AS LM SSR LJD. Wrote the paper: OEL CMJ DGP SSG.

References

1. Freda PU (2002) Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87: 3013–3018.
2. Azza M, Copp DH, Zanelli JM (1995) 25 years of salmon calcitonin: from synthesis to therapeutic use. Calcif Tissue Int 57: 405–408.
3. Chesnut CH 3rd, Azza M, Silverman S, Engellhardt M, Olson M, et al. (2008) Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos Int 19: 497–501.
4. Kraenzlin ME, Meier C (2011) Parathyroid hormone analogues in the treatment of osteoporosis. Nat Rev Endocrinol 7: 647–656.
5. Mannucci PM (1997) Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 90: 2515–2521.
6. Yamamoto Y, Tsutsumi Y, Yoshioka Y, Nishibata T, Kobayashi K, et al. (2003) Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat Biotechnol 21: 546–552.
7. Alters SE, McLaughlin B, Spink B, Lachinian T, Wang CW, et al. (2012) GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn’s disease model. PLoS One 7: e50630.
8. Schellenberger V, Wang CW, Geething NC, Spink BJ, Campbell A, et al. (2009) A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol 27: 1198–1200.
9. Ashkenazi A, Chavon SM (1997) Immunoadhesins as research tools and therapeutic agents. Curr Opin Immunol 9: 195–200.

10. Jazayeri JA, Carroll GJ (2008) Fc-based cytokines : prospects for engineering superior therapeutics. BioDrugs 22: 11–26.
11. Jimenez-Sedelm R, Rasmussen MH, Chrisense M, Knop FK (2010) Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes. Curr Opin Mol Ther 12: 790–797.
12. Baggio LL, Huang Q, Brown TJ, Drakey RJ (2004) A recombinant human glucagon-like peptide (GLP-1)–albumin protein (albugon) mimics peptide-like activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53: 2492–2500.
30. de Chateau M, Bjorck L (1994) Protein PAB, a mosaic albumin-binding modules. J Biol Chem 277: 8114–8120.

29. Knudsen LB (2010) Liraglutide: the therapeutic promise from animal models. Diabetes: A Pilot Study. PLoS One 5: e11219.

28. Baruah MP, Chaudhury T, Sethi BK, Dharmalingam M (2012) Liraglutide in diabetes mellitus. J Clin Pharm Ther 40: 503–512.

27. Keating GM (2012) Insulin detemir: a review of its use in the management of type 2 diabetes mellitus. Drugs 72: 2255–2287.

26. Havelund S, Plum A, Ribel U, Jonassen I, Volund A, et al. (2004) The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 21: 1498–1504.

25. McCurdy TR, Gataincie S, Eltringham-Smith LJ, Sheffield WP (2004) A bacterial protein representing the first contemporary example of module shuffling. J Biol Chem 269: 12147–12151.

24. Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7: 713–725.

23. Anderson CL, Chaudhury C, Kim J, Bronson CL, Wani MA, et al. (2006) Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J Biol Chem 281: 5234–5241.

22. Andersen JT, Sandlie I (2009) The versatile MHC class I-related FcRn protects proteins. J Biol Chem 284: 16291–16297.

21. Markussen J, Havelund S, Kurtzhals P, Andersen AS, Halstrom J, et al. (1996) Soluble, fatty acid acylated insulin binds to albumin and show protracted action in pigs. Diabetologia 39: 201–208.

20. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Larsen UD, et al. (1995) Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 270: 35035–35043.

19. Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, et al. (2002) Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 277: 35035–35043.

18. Deacon CF (2009) Potential of liraglutide in the treatment of patients with type 2 diabetes. Vasc Health Risk Manag 5: 199–211.

17. Nelson-Piercy C, Hammond PJ, Gwilliam ME, Khandan-Nia N, Myers MJ, et al. (1996) Mutational analysis of the human serum albumin binding domain of streptococcal protein G and human serum albumin. Protein Sci 5: 206–213.

16. Andersen JT, Pedersen H, Kormann J, Daae MB, Abrahmsen L, et al. (2011) Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J Biol Chem 286: 5234–5241.

15. Hargrove DM, Kendall ES, Reynolds JM, Lwin AN, Herich JP, et al. (2007) Biological activity of AC3174, a peptide analog of exendin-4. Regul Pept 139: 113–119.

14. Fineman M, Flanagan S, Taylor K, Asporna M, Shen LZ, et al. (2011) Pharmacokinetics and pharmodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet 50: 65–74.

13. Mack CM, Moore CX, Jodha CM, Bhavsar S, Wilson JK, et al. (2006) Antihyperglycemic action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 30: 1332–1340.

12. Knudsen LB (2004) Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes mellitus. J Med Chem 47: 4120–4134.

11. Thorens B, Porret A, Buhrer L, Deng SP, Morel P, et al. (1993) Cloning and functional expression of the human incret GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9–39) an antagonist of the receptor. Diabetes 42: 1678–1682.

10. Raufman JP (1996) Bioactive peptides from lizard venom. Regul Pept 61: 1–18.

9. Young AA, Gedulin BR, Bhavsar S, Boilkin N, Jodha C, et al. (1999) Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48: 1026–1034.

8. Nelson-Piercy C, Hammond PJ, Gwilliam ME, Khandan-Nia N, Myers MJ, et al. (1996) Effect of a new oral somatostatin analog (SDZ CO 611) on gastric emptying, mouse to circulate transit time, and pancreatic and gut hormone release in normal male subjects. J Clin Endocrinol Metab 78: 329–336.

7. Henriksen K, Bay-Jensen AC, Christiansen C, Karsdal MA (2010) Oral salmon calcitonin pharmacology in osteoporosis. Expert Opin Biol Ther 10: 1617–1629.

6. Eldor R, Arbit E, Corcos A, Kidron M (2015) Glucose-Reducing Effect of the ORMD-0801 Oral Insulin Preparation in Patients with Uncontrolled Type 1 Diabetes: A Pilot Study. PLoS One 8: e058242.